Lesson plan

IS-159

IS-159, also known as serotonin-O-carboxymethylglycyltyrosinamide, is a triptan-like serotonin 5-HT 1B and 5-HT 1D receptor agonist which was under development for the treatment of migraine but was never marketed. It is taken intranasally or subcutaneously. The drug is a small serotonin-containing peptide and is described as being peripherally selective. It acts as a selective and potent serotonin 5-HT 1B and 5-HT 1D receptor agonist (K i = 3.2 nM and 1.6 nM, respectively). IS-159 has more than 300-fold lower affinity for the serotonin 5-HT 1A receptor (K i = 1,000) and is inactive at the serotonin 5-HT 1E and 5-HT 1F receptors (K i = >10,000 nM). The drug's pharmacokinetics in humans have been studied. IS-159 was originated by Immunotech in France and was under development by Immunotech and The Medicines Company in the 1990s and early 2000s, but development was discontinued in 2003. The drug reached phase 2 clinical trials prior to the discontinuation of its development.

Back to article

Article summary

IS-159, also known as serotonin-O-carboxymethylglycyltyrosinamide, is a triptan-like serotonin 5-HT 1B and 5-HT 1D receptor agonist which was under development for the treatment of migraine but was never marketed. It is taken intranasally or subcutaneously. The drug is a small serotonin-containing peptide and is described as being peripherally selective. It acts as a selective and potent serotonin 5-HT 1B and 5-HT 1D receptor agonist (K i = 3.2 nM and 1.6 nM, respectively). IS-159 has more than 300-fold lower affinity for the serotonin 5-HT 1A receptor (K i = 1,000) and is inactive at the serotonin 5-HT 1E and 5-HT 1F receptors (K i = >10,000 nM). The drug's pharmacokinetics in humans have been studied. IS-159 was originated by Immunotech in France and was under development by Immunotech and The Medicines Company in the 1990s and early 2000s, but development was discontinued in 2003. The drug reached phase 2 clinical trials prior to the discontinuation of its development.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.